Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 9Pancreatic Neoplasms 7Glioblastoma 7Carcinoma, Non-Small-Cell Lung 5Breast Neoplasms 4Triple Negative Breast Neoplasms 3Ovarian Neoplasms 3Neoplasms 3Lung Neoplasms 3Colonic Neoplasms 3Urinary Bladder Neoplasms 2Prostatic Neoplasms 2Osteosarcoma 2Myelodysplastic Syndromes 2Lymphoma, Follicular 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Glioma 2Fibrolamellar hepatocellular carcinoma 2Fallopian Tube Neoplasms 2Colorectal Neoplasms 2Carcinoma, Merkel Cell 2Carcinoma, Hepatocellular 2Carcinoma 2Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urologic Neoplasms 1Thrombocythemia, Essential 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1

Interventions

Nivolumab 2radium Ra 223 dichloride 1poly ICLC 1fludarabine phosphate 1fludarabine 1darolutamide 1cabozantinib 1bempegaldesleukin 1Radium-223 1Radiosurgery 1Pluvicto 1Cyclophosphamide 1Blood Specimen Collection 1Abiraterone Acetate 1177Lu-EB-PSMA-617 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Metastatic Castration-resistant Prostate Cancer × poly ICLC × Clear all
NCT03835533 2024-04-12

PORTER

Parker Institute for Cancer Immunotherapy

Phase 1 Completed
43 enrolled 19 charts
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡